Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.

Wang MT, Fer N, Galeas J, Collisson EA, Kim SE, Sharib J, McCormick F.

Nat Commun. 2019 Jul 11;10(1):3055. doi: 10.1038/s41467-019-11044-9.

PMID:
31296870
Free PMC Article
2.

Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.

Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T.

Nature. 2019 May;569(7754):131-135. doi: 10.1038/s41586-019-1130-6. Epub 2019 Apr 17.

PMID:
30996350
3.

Molecular subtypes of pancreatic cancer.

Collisson EA, Bailey P, Chang DK, Biankin AV.

Nat Rev Gastroenterol Hepatol. 2019 Apr;16(4):207-220. doi: 10.1038/s41575-019-0109-y. Review.

PMID:
30718832
4.

Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma.

Torphy RJ, Wang Z, True-Yasaki A, Volmar KE, Rashid N, Yeh B, Anderson JM, Johansen JS, Hollingsworth MA, Yeh JJ, Collisson EA.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00121. Epub 2018 Jan 16.

5.

Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.

Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH.

Fam Cancer. 2019 Apr;18(2):241-251. doi: 10.1007/s10689-018-0106-2.

PMID:
30267352
6.

Bringing Pancreas Cancer into the Lab.

Collisson EA.

Cancer Discov. 2018 Sep;8(9):1062-1063. doi: 10.1158/2159-8290.CD-18-0811.

PMID:
30181169
7.

APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.

Cho RJ, Alexandrov LB, den Breems NY, Atanasova VS, Farshchian M, Purdom E, Nguyen TN, Coarfa C, Rajapakshe K, Prisco M, Sahu J, Tassone P, Greenawalt EJ, Collisson EA, Wu W, Yao H, Su X, Guttmann-Gruber C, Hofbauer JP, Hashmi R, Fuentes I, Benz SC, Golovato J, Ehli EA, Davis CM, Davies GE, Covington KR, Murrell DF, Salas-Alanis JC, Palisson F, Bruckner AL, Robinson W, Has C, Bruckner-Tuderman L, Titeux M, Jonkman MF, Rashidghamat E, Lwin SM, Mellerio JE, McGrath JA, Bauer JW, Hovnanian A, Tsai KY, South AP.

Sci Transl Med. 2018 Aug 22;10(455). pii: eaas9668. doi: 10.1126/scitranslmed.aas9668.

PMID:
30135250
8.

Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.

Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA.

AJR Am J Roentgenol. 2018 Nov;211(5):1010-1019. doi: 10.2214/AJR.18.19602. Epub 2018 Jul 31.

PMID:
30063366
9.

Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma.

North JP, Golovato J, Vaske CJ, Sanborn JZ, Nguyen A, Wu W, Goode B, Stevers M, McMullen K, Perez White BE, Collisson EA, Bloomer M, Solomon DA, Benz SC, Cho RJ.

Nat Commun. 2018 May 14;9(1):1894. doi: 10.1038/s41467-018-04008-y.

10.

Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion.

Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK.

Oncologist. 2018 Sep;23(9):998-1003. doi: 10.1634/theoncologist.2017-0645. Epub 2018 Apr 5.

PMID:
29622700
11.

Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.

Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS.

Oncotarget. 2017 Oct 26;8(58):97769-97786. doi: 10.18632/oncotarget.22080. eCollection 2017 Nov 17.

12.

Advances in the Genetics and Biology of Pancreatic Cancer.

Aguirre AJ, Collisson EA.

Cancer J. 2017 Nov/Dec;23(6):315-320. doi: 10.1097/PPO.0000000000000286. Review.

PMID:
29189326
13.

Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.

Korkola JE, Collisson EA, Heiser LM, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW.

PLoS One. 2017 Oct 11;12(10):e0186551. doi: 10.1371/journal.pone.0186551. eCollection 2017.

14.

MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.

Lu X, Peled N, Greer J, Wu W, Choi P, Berger AH, Wong S, Jen KY, Seo Y, Hann B, Brooks A, Meyerson M, Collisson EA.

Cancer Res. 2017 Aug 15;77(16):4498-4505. doi: 10.1158/0008-5472.CAN-16-1944. Epub 2017 May 18.

15.

Pancreatic Cancer Genomics 2.0: Profiling Metastases.

Collisson EA, Maitra A.

Cancer Cell. 2017 Mar 13;31(3):309-310. doi: 10.1016/j.ccell.2017.02.014.

16.

Pancreatic Cancer: Progress and Challenges in a Rapidly Moving Field.

Collisson EA, Olive KP.

Cancer Res. 2017 Mar 1;77(5):1060-1062. doi: 10.1158/0008-5472.CAN-16-2452. Epub 2017 Feb 16.

17.

Stromal cues regulate the pancreatic cancer epigenome and metabolome.

Sherman MH, Yu RT, Tseng TW, Sousa CM, Liu S, Truitt ML, He N, Ding N, Liddle C, Atkins AR, Leblanc M, Collisson EA, Asara JM, Kimmelman AC, Downes M, Evans RM.

Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1129-1134. doi: 10.1073/pnas.1620164114. Epub 2017 Jan 17.

18.

The Authors Respond.

Chapman JS, Collisson EA, Taylor BS.

J Natl Compr Canc Netw. 2016 Mar;14(3):lxviii. No abstract available.

PMID:
27396027
19.

Election 2016: Voting on Variants.

Cho RJ, Collisson EA.

Cancer Discov. 2016 Jul;6(7):694-6. doi: 10.1158/2159-8290.CD-16-0559.

20.

An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.

Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL.

Cancer Lett. 2016 Sep 28;380(1):144-52. doi: 10.1016/j.canlet.2016.06.017. Epub 2016 Jun 22.

PMID:
27343980

Supplemental Content

Loading ...
Support Center